{"id":1016087,"date":"2026-11-02T10:54:07","date_gmt":"2026-11-02T15:54:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/"},"modified":"2026-11-02T10:54:07","modified_gmt":"2026-11-02T15:54:07","slug":"monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/","title":{"rendered":"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WILMETTE, Ill., Nov.  02, 2026  (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting<sup>\u00ae<\/sup> 2026, taking place Nov. 5\u20139, 2026, at the Colorado Convention Center in Denver, Colorado.<\/p>\n<p align=\"justify\">As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-na\u00efve and treatment-experienced patients. These findings will also be available as a companion e-poster via the AASLD website.<\/p>\n<p align=\"justify\">Additionally, Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., will present a poster on molybdenum balance in patients treated with ALXN1840.<\/p>\n<p>\n        <strong>Presentation Details<\/strong>\n      <\/p>\n<p>\n        <strong><br \/>\n          <em>Oral Presentation<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>Residual Hepatic, Neurologic, and Psychiatric Disease Burden in Treatment-Experienced Patients with Wilson Disease: Baseline Findings from the FoCus Phase 3 Trial<br \/><strong>Presenter: <\/strong>Frederick K. Askari, M.D., Ph.D., Associate Professor of Internal Medicine and Director of the Wilson Disease Program, University of Michigan Health System<br \/><strong>Session: <\/strong>Mapping the Future for Liver Health: Metabolic and Genetic Disease Discoveries<br \/><strong>Publication Number: <\/strong>0198<br \/><strong>Date and Time: <\/strong>Sunday, Nov. 8, 2026, 12:15 p.m. to 12:30 p.m. MT<\/p>\n<p>\n        <strong><br \/>\n          <em>Companion E-Poster <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Availability: <\/strong>An e-poster of the oral presentation will be available via the AASLD website.<strong><em>\u00a0<\/em><\/strong><\/p>\n<p>\n        <strong><br \/>\n          <em>Poster Presentation<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Title: <\/strong>Neutral Molybdenum Balance and Lack of Molybdenum Toxicity in Subjects Treated with Tiomolibdate Choline Supports Safety Profile of TMC<br \/><strong>Presenter: <\/strong>Professor Aftab Ala, MBBS, M.D., FRCP, Ph.D., Consultant Hepatologist, Institute of Liver Studies, King\u2019s College Hospital NHS Foundation Trust, London<br \/><strong>Session: <\/strong>Poster Session I: Metabolic and Genetic Disease<br \/><strong>Publication Number: <\/strong>1420<br \/><strong>Date and Time: <\/strong>Thursday, Nov. 5, 2026, 12:00 p.m. to 1:00 p.m. MT<\/p>\n<p align=\"justify\">The abstracts are available on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0InxJCXF1czNtjM7RXqauWRlHFQJQvoKEj1tM44LKzBDa9wrSGHH5IcuwuAbGhrWX7CbyFfoMhOaIB2rgWYhxeMu-_t5tJ5llsZHbK__6nPpPKaz2sASv7lOxTDjcYGgxhv6XqOE5V2L-jJulONalxsUoF45_6AEYxGmBvih-_w=\" rel=\"nofollow\" target=\"_blank\">AASLD conference website<\/a>. Presentation materials will be made available in the Investors section of Monopar\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bf-Vd3tT0H9tkwBQF1YwF0ZHblf964Wcdjh8fZ8gLsAVtOGk74I0K55fpfnxhBVME4v3eWoiw05Na7OW6AA6J71jhV5NFjkLKuUEb2W5AQ8=\" rel=\"nofollow\" target=\"_blank\">www.monopartx.com<\/a> following each presentation.<\/p>\n<p>\n        <strong>About Wilson Disease<\/strong>\n      <\/p>\n<p align=\"justify\">Wilson disease is a rare genetic disorder that affects approximately 1 in 30,000 people worldwide. Caused by mutations in the ATP7B gene, the disease impairs the body\u2019s ability to excrete copper, resulting in toxic copper accumulation in the liver, brain, and other organs and potentially fatal outcomes if untreated.<\/p>\n<p>\n        <strong>About ALXN1840<\/strong>\n      <\/p>\n<p align=\"justify\">ALXN1840 (tiomolibdate choline, TMC) is a novel first-in-class albumin tripartite complex (ATC) activator under investigation for the treatment of Wilson disease. ALXN1840 rapidly mobilizes and tightly sequesters excess copper in ATCs, suppressing its redox reactivity, limiting oxidative damage, and blocking transport across the blood\u2013brain barrier. Clinical data demonstrate that ALXN1840 improves copper balance by increasing fecal copper excretion. In the Phase 3 pivotal trial, ALXN1840 met the primary endpoint by demonstrating rapid and sustained copper mobilization significantly greater than standard of care over 48 weeks in both previously treated and untreated patients. Durable clinical improvement and a favorable safety and tolerability profile were observed across 645 patient-years of follow-up in 266 patients.<\/p>\n<p>\n        <strong>About Monopar Therapeutics Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Monopar Therapeutics is a clinical-stage biopharmaceutical company with late-stage candidate ALXN1840 for Wilson disease, and radiopharmaceutical programs including MNPR-101-Zr (Phase 1) for imaging advanced cancers along with MNPR-101-Lu (Phase 1a) and MNPR-101-Ac (late preclinical) for the treatment of advanced cancers. For more information, visit: www.monopartx.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements involve risks and uncertainties including, but not limited to, uncertainties related to the regulatory and approval process for ALXN1840, and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar\u2019s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar\u2019s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.<\/p>\n<p>\n        <strong>CONTACT:<\/strong>\n      <\/p>\n<p>Monopar Therapeutics Inc.<br \/>Investor Relations<br \/>Quan Vu<br \/>Chief Financial Officer<br \/>vu@monopartx.com<\/p>\n<p>Follow Monopar on social media for updates:<br \/>X: @MonoparTx | LinkedIn: Monopar Therapeutics<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NWNkZTEwZTEtMmI0OS00NWRhLWI5MmUtZmI3OGI2ODYyZmFhLTEyMDU0MTYtMjAyNi0xMS0wMi1lbg==\/tiny\/Monopar-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting\u00ae 2026, taking place Nov. 5\u20139, 2026, at the Colorado Convention Center in Denver, Colorado. As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-na\u00efve and treatment-experienced patients. These findings &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016087","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting\u00ae 2026, taking place Nov. 5\u20139, 2026, at the Colorado Convention Center in Denver, Colorado. As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-na\u00efve and treatment-experienced patients. These findings &hellip; Continue reading &quot;Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T15:54:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data\",\"datePublished\":\"2026-11-02T15:54:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/\"},\"wordCount\":808,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/\",\"name\":\"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=\",\"datePublished\":\"2026-11-02T15:54:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/","og_locale":"en_US","og_type":"article","og_title":"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - Market Newsdesk","og_description":"WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Monopar Therapeutics Inc. (\u201cMonopar\u201d or the \u201cCompany\u201d) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that two abstracts related to ALXN1840 (tiomolibdate choline, TMC), the Company\u2019s investigational therapy for Wilson disease, will be presented at the American Association for the Study of Liver Diseases (AASLD) \u2013 The Liver Meeting\u00ae 2026, taking place Nov. 5\u20139, 2026, at the Colorado Convention Center in Denver, Colorado. As previously announced, Frederick K. Askari, M.D., Ph.D., will deliver an oral presentation highlighting the baseline Wilson disease characteristics from the Phase 3 FoCus trial characterizing hepatic, neurologic, and psychiatric disease burden in both treatment-na\u00efve and treatment-experienced patients. These findings &hellip; Continue reading \"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-02T15:54:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data","datePublished":"2026-11-02T15:54:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/"},"wordCount":808,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/","name":"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=","datePublished":"2026-11-02T15:54:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg1NzM5MiM3OTI3Nzc5IzIxOTM4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn1840-molybdenum-safety-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Monopar to Present at AASLD \u2013 The Liver Meeting\u00ae 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016087"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016087\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}